Special considerations in pediatric asthma.

Curr Opin Pharmacol

University of Miami-Miller School of Medicine, Department of Pediatrics, Division of Pediatric Pulmonology, 1st Floor, Batchelor Children's Research Institute, 1580 NW 10th Avenue, Miami, FL 33136, United States.

Published: June 2010

Asthma is the most common chronic illness in childhood with challenges that revolve around interventions that can potentially alter the course of the disease and concerns regarding the safety of regular use of controller medications. Recent studies suggest that the use of inhaled corticosteroids in very young children with frequent wheezing episodes and at high risk for asthma, while effective, does not alter the eventual progression to asthma. As a controller medication, the safety of inhaled corticosteroids as regards efficacy and risk are reviewed. The use of as-needed ICS as a strategy to reduce risk of adverse events can be explored in children with mild persistent asthma. The key to risk reduction is to titrate the dose of steroids to the lowest dose needed to achieve asthma control. Aside from inhaled corticosteroids, other controller medications are described within the framework of the updated asthma guidelines released by the NIH-National Asthma Education and Prevention Program in 2007. Other interventions that may attenuate asthma risk and severity include environmental measures towards allergen avoidance and attention to the increasing prevalence of obesity. The use of age-appropriate delivery systems for inhaled medications is also important for asthma control.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2010.04.012DOI Listing

Publication Analysis

Top Keywords

inhaled corticosteroids
12
asthma
10
controller medications
8
asthma control
8
risk
5
special considerations
4
considerations pediatric
4
pediatric asthma
4
asthma asthma
4
asthma common
4

Similar Publications

Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS.

J Family Med Prim Care

December 2024

Medicines Evaluation Unit, Manchester University National Health Service Foundation Trust, University of Manchester, Manchester, United Kingdom.

Context: An inhaled corticosteroid (ICS) in combination with a long-acting β2-agonist (LABA) is a common treatment approach for asthma patients not controlled on ICS alone, but a significant proportion of patients remain uncontrolled on this combination and treatment adherence can also be a challenge. One of the options for adults whose asthma is uncontrolled in an ICS/LABA is the addition of a long-acting muscarinic receptor antagonist (LAMA), an approach commonly referred to as 'triple therapy'. The use of medium-strength ICS/LABA/LAMA is established in treating chronic obstructive pulmonary disease but is less well-established in asthma.

View Article and Find Full Text PDF

Background: Biologics can induce remission in some patients with severe asthma, however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term trajectories of disease progression in patients initiating biologics and investigate trajectory associations with disease burden and impact on biologic therapy efficacy.

Methods: Patients in the Danish Severe Asthma Registry initiating biologic therapy between 2016-2022 were included and followed retrospectively in prescription databases starting 1995.

View Article and Find Full Text PDF

Objective: It remains unclear whether baseline FENO levels can predict response to anti-IL5/5R biologic treatment in patients with severe asthma.

Methods: We recruited 104 patients with severe eosinophilic asthma treated with anti-IL5/anti-IL5R for at least one year who had measured FeNO values before the beginning of anti-eosinophilic treatment. Population was divided into subjects with FeNO < 25 and ≥25 ppb.

View Article and Find Full Text PDF

Background/aims: Chronic obstructive pulmonary disease (COPD) management guidelines have increasingly emphasised the importance of exacerbation prevention, and the role of blood eosinophil count (BEC) as a biomarker for inhaled corticosteroids (ICS) response. This study aimed to describe the distribution and stability of BEC and understand real-world treatment patterns among COPD patients in South Korea.

Methods: This was a retrospective database analysis using data obtained from the KOrea COPD Subgroup Study (KOCOSS) registry between January 2012 and August 2018.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!